The American Journal of Managed Care22h
GPP Flares Linked to Increased Hospitalizations, Health Care Costs, Study Finds
New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...
Hosted on MSN1d
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...
Too Old to Operate8d
Consensus on Treatment Goals for Generalized Pustular Psoriasis
The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...
H.C. Wainwright maintains AnaptysBio stock Neutral rating, $19 target
AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Medscape11d
A Case of Paracetamol-Induced Acute Generalized Exanthematous Pustulosis in a Pregnant Woman Localized in the Neck Region
Recent studies imply that acute generalized exanthematous pustulosis ... while Th-1-derived dermatoses, such as psoriasis and sarcoidosis, are ameliorated. AGEP, a neutrophile, cell-mediated ...
pharmaphorum5y
AbbVie's psoriasis drug Skyrizi approved in Japan
This is the first approval by a regulator for Skyrizi, with the Japanese Ministry of Health Labour and Welfare granting a licence for plaque psoriasis, generalised pustular psoriasis ...
Vanda, Anaptys Join on Development Pact
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...